

1. Sales January to December 2006 and 2005

	2006	2005	% change	
	CHF m	CHF m	In CHF	In local currencies
January – December				
Pharmaceuticals Division	33,294	27,268	+22	+21
Roche Pharmaceuticals	20,666	16,955	+22	+20
Genentech	9,125	6,614	+38	+37
Chugai	3,503	3,699	-5	-1
Diagnostics Division	8,747	8,243	+6	+5
Roche Group	42,041	35,511	+18	+17

2. Quarterly local sales growth by Division in 2006

	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005
Pharmaceuticals Division	+19	+19	+25	+22
Roche Pharmaceuticals	+19	+15	+25	+20
Genentech	+40	+39	+33	+37
Chugai	-8	+1	+2	+2
Diagnostics Division	+3	+5	+6	+5
Roche Group	+15	+16	+20	+18

3. Quarterly sales by Division in 2006

CHF millions	Q4 2005	Q1 2006	Q2 2006	Q3 2006	Q4 2006
Pharmaceuticals Division	7,834	7,739	7,838	8,335	9,382
Roche Pharmaceuticals	4,786	4,821	4,849	5,251	5,745
Genentech	1,982	2,056	2,167	2,299	2,603
Chugai	1,066	862	822	785	1,034
Diagnostics Division	2,235	2,091	2,181	2,143	2,332
Roche Group	10,069	9,830	10,019	10,478	11,714

4. Top 20 Pharmaceuticals Division product sales<sup>1</sup> and local growth<sup>2</sup> in YTD December 2006: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	4,839	15%	2,696	12%	194	1%	1,949	23%
Herceptin	3,927	81%	1,547	65%	156	30%	2,224	100%
Avastin	2,962	76%	2,188	54%	-	-	774	200%
Tamiflu	2,627	68%	912	130%	409	8%	1,306	67%
NeoRecormon/Epogin	2,227	-1%	-	-	683	-12%	1,544	6%
CellCept	1,842	7%	941	14%	32	17%	869	-1%
Pegasys	1,467	3%	447	-10%	62	-28%	958	14%
Xeloda	971	20%	383	21%	27	-6%	561	21%
Tarceva	813	108%	504	46%	-	-	309	586%
Xenical	693	7%	114	14%	-	-	579	6%
Xolair	537	31%	537	31%	-	-	-	-
Kytril	498	0%	195	-4%	139	6%	164	1%
Nutropin	494	3%	479	3%	-	-	15	8%
Bonviva/Boniva	488	462%	413	400%	-	-	75	1768%
Cymevene/Valcyte	488	22%	259	27%	-	-	229	18%
Lucentis	478	-	478	-	-	-	-	-
Pulmozyme	436	10%	250	7%	-	-	186	13%
Rocephin	416	-56%	25	-95%	59	1%	332	-13%
Neutrogen	379	9%	-	-	379	9%	-	-
Activase/TNKase	362	15%	315	14%	-	-	47	21%

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined <sup>2</sup> versus YTD December 2005

5. Top 20 Pharmaceuticals Division quarterly local product sales growth<sup>1</sup> in 2006

	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005
MabThera/Rituxan	16%	16%	13%	17%
Herceptin	107%	103%	72%	58%
Avastin	141%	102%	55%	49%
Tamiflu	37%	133%	141%	43%
NeoRecormon/Epogin	3%	0%	-4%	-1%
CellCept	15%	-1%	7%	7%
Pegasys	2%	3%	1%	6%
Xeloda	35%	21%	13%	16%
Tarceva	182%	119%	110%	71%
Xenical	16%	8%	-1%	6%
Xolair	39%	30%	34%	23%
Kytril	18%	-4%	0%	-10%
Nutropin	-3%	1%	5%	8%
Bonviva/Boniva	-	323%	929%	251%
Cymevene/Valcyte	21%	12%	26%	30%
Lucentis	-	-	-	-
Pulmozyme	14%	4%	8%	11%
Rocephin	-69%	-63%	-35%	-32%
Neutrogen	19%	12%	1%	7%
Activase/TNKase	19%	21%	9%	14%

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined

6. Pharmaceuticals Division quarterly local product sales growth<sup>1</sup> US in 2006

	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005
MabThera/Rituxan	7%	16%	9%	15%
Herceptin	123%	110%	40%	29%
Avastin	96%	72%	34%	36%
Tamiflu	414%	143%	229%	33%
NeoRecormon/Epogin	-	-	-	-
CellCept	32%	6%	9%	13%
Pegasys	-14%	-10%	-11%	-6%
Xeloda	40%	24%	11%	16%
Tarceva	95%	46%	37%	27%
Xenical	24%	15%	6%	11%
Xolair	39%	30%	34%	23%
Kytril	31%	-20%	5%	-26%
Nutropin	-3%	1%	5%	8%
Bonviva/Boniva	-	262%	818%	205%
Cymevene/Valcyte	15%	20%	32%	38%
Lucentis	-	-	-	-
Pulmozyme	12%	0%	7%	8%
Rocephin	-96%	-96%	-89%	-94%
Neutrogen	-	-	-	-
Activase/TNKase	19%	19%	9%	11%

<sup>1</sup> Roche Pharmaceuticals and Genentech combined

7. Pharmaceuticals Division quarterly local product sales growth Japan<sup>1</sup> in 2006

	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005
MabThera/Rituxan	3%	-1%	3%	1%
Herceptin	31%	30%	33%	26%
Avastin	-	-	-	-
Tamiflu	-33%	367%	6485%	36%
NeoRecormon/Epogin	-3%	-9%	-22%	-12%
CellCept	15%	20%	19%	14%
Pegasys	-11%	-24%	-34%	-37%
Xeloda	1%	-5%	-9%	-9%
Tarceva	-	-	-	-
Xenical	-	-	-	-
Xolair	-	-	-	-
Kytril	6%	9%	4%	5%
Nutropin	-	-	-	-
Bonviva/Boniva	-	-	-	-
Cymevene/Valcyte	-	-	-	-
Lucentis	-	-	-	-
Pulmozyme	-	-	-	-
Rocephin	-11%	8%	2%	4%
Neutrogen	19%	12%	1%	7%
Activase/TNKase	-	-	-	-

<sup>1</sup> Chugai

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World<sup>1</sup> in 2006

	Q1 2006 vs. Q1 2005	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005
MabThera/Rituxan	30%	20%	20%	22%
Herceptin	105%	107%	104%	87%
Avastin	654%	294%	162%	101%
Tamiflu	88%	124%	49%	52%
NeoRecormon/Epogin	6%	5%	6%	5%
CellCept	2%	-7%	4%	0%
Pegasys	12%	13%	11%	19%
Xeloda	34%	20%	16%	17%
Tarceva	-	2566%	867%	211%
Xenical	14%	7%	-3%	5%
Xolair	-	-	-	-
Kytril	13%	4%	-9%	-5%
Nutropin	12%	-4%	10%	14%
Bonviva/Boniva	-	-	-	885%
Cymevene/Valcyte	27%	5%	19%	21%
Lucentis	-	-	-	-
Pulmozyme	18%	10%	10%	16%
Rocephin	-24%	-9%	-8%	-10%
Neutrogen	-	-	-	-
Activase/TNKase	14%	33%	7%	31%

<sup>1</sup> Roche Pharmaceuticals

9. Top Pharmaceuticals Division quarterly product sales<sup>1</sup> in 2005 and 2006

CHF millions	Q4 2005	Q1 2006	Q2 2006	Q3 2006	Q4 2006
MabThera/Rituxan	1,153	1,146	1,202	1,177	1,314
Herceptin	704	861	952	1,009	1,105
Avastin	572	676	713	741	832
Tamiflu	699	601	360	669	997
NeoRecormon/Epogin	602	535	565	535	592
CellCept	464	454	437	466	485
Pegasys	373	350	374	350	393
Xeloda	228	238	234	239	260
Tarceva	141	172	195	211	235
Xenical	161	181	182	160	170
Xolair	123	124	133	135	145
Kytril	135	130	124	127	117
Nutropin	128	118	126	118	132
Bonviva/Boniva	51	75	92	142	179
Cymevene/Valcyte	109	110	113	126	139
Lucentis	-	-	13	192	273
Pulmozyme	107	109	103	108	116
Rocephin	161	110	106	96	104
Neutrogen	98	93	95	91	100
Activase/TNKase	87	88	90	89	95

<sup>1</sup> Roche Pharmaceuticals, Genentech and Chugai combined

10. Pharmaceuticals Division quarterly product sales<sup>1</sup> in US in 2005 and 2006

CHF millions	Q4 2005	Q1 2006	Q2 2006	Q3 2006	Q4 2006
MabThera/Rituxan	672	634	675	650	737
Herceptin	321	375	400	374	398
Avastin	462	516	527	539	606
Tamiflu	210	168	108	361	275
NeoRecormon/Epogin	-	-	-	-	-
CellCept	244	221	215	241	264
Pegasys	137	103	115	107	122
Xeloda	99	92	90	90	111
Tarceva	108	120	129	123	132
Xenical	26	34	28	25	27
Xolair	123	124	133	135	145
Kytril	56	57	43	56	39
Nutropin	124	114	123	115	127
Bonviva/Boniva	48	69	78	122	144
Cymevene/Valcyte	57	55	59	68	77
Lucentis	-	-	13	192	273
Pulmozyme	63	64	58	62	66
Rocephin	48	9	8	6	2
Neutrogen	-	-	-	-	-
Activase/TNKase	77	78	78	78	81

<sup>1</sup> Roche Pharmaceuticals and Genentech combined

11. Pharmaceuticals Division quarterly product sales<sup>1</sup> in Japan in 2005 and 2006

CHF millions	Q4 2005	Q1 2006	Q2 2006	Q3 2006	Q4 2006
MabThera/Rituxan	59	41	48	49	56
Herceptin	38	32	38	40	46
Avastin	-	-	-	-	-
Tamiflu	133	170	9	57	173
NeoRecormon/Epogin	232	160	182	147	194
CellCept	9	7	8	8	9
Pegasys	25	17	16	14	15
Xeloda	8	6	7	7	7
Tarceva	-	-	-	-	-
Xenical	-	-	-	-	-
Xolair	-	-	-	-	-
Kytril	40	29	36	34	40
Nutropin	-	-	-	-	-
Bonviva/Boniva	-	-	-	-	-
Cymevene/Valcyte	-	-	-	-	-
Lucentis	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Rocephin	17	13	16	13	17
Neutrogen	98	93	95	91	100
Activase/TNKase	-	-	-	-	-

<sup>1</sup> Chugai

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World<sup>1</sup> in 2005 and 2006

CHF millions	Q4 2005	Q1 2006	Q2 2006	Q3 2006	Q4 2006
MabThera/Rituxan	422	471	479	478	521
Herceptin	345	454	514	595	661
Avastin	110	160	186	202	226
Tamiflu	356	263	243	251	549
NeoRecormon/Epogin	370	375	383	388	398
CellCept	211	226	214	217	212
Pegasys	211	230	243	229	256
Xeloda	121	140	137	142	142
Tarceva	33	52	66	88	103
Xenical	135	147	154	135	143
Xolair	-	-	-	-	-
Kytril	39	44	45	37	38
Nutropin	4	4	3	3	5
Bonviva/Boniva	3	6	14	20	35
Cymevene/Valcyte	52	55	54	58	62
Lucentis	-	-	-	-	-
Pulmozyme	44	45	45	46	50
Rocephin	96	88	82	77	85
Neutrogen	-	-	-	-	-
Activase/TNKase	10	10	12	11	14

<sup>1</sup> Roche Pharmaceuticals